SCHEMBL20149361

SCHEMBL20149361

O=C(O)c1cc(-c2ccc(Oc3ccc(Cl)cc3)cc2)on1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDH1 P12830 1/20 1.00
CTNNB1 P35222 1/20 1.00
TCF7L2 Q9NQB0 1/20 1.00
ALDH1A1 P00352 4/20 0.67
HPGD P15428 2/20 0.67
MAPT P10636 1/20 0.67
RECQL P46063 1/20 0.67
PTPN1 P18031 2/20 0.59
THRB P10828 1/20 0.57
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 2/20 0.51
MAPK1 P28482 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892967 0.91 CDH1 (0.82) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL18257901 0.82 CDH1 (0.70) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL892240 0.80 HPGD (1.00) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL16401825 0.78 CDH1 (0.63) CDH1CTNNB1TCF7L2ALDH1A1MAPT
SCHEMBL11902926 0.77 ALDH1A1 (0.67) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL11275129 0.76 CDH1 (0.61) CDH1CTNNB1TCF7L2ALDH1A1MAPT
SCHEMBL72786 0.76 ALDH1A1 (1.00) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL71299 0.76 ALDH1A1 (1.00) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL11902059 0.75 CDH1 (0.59) CDH1CTNNB1TCF7L2ALDH1A1HPGD
SCHEMBL1178695 0.74 ALDH1A1 (0.72) CDH1CTNNB1TCF7L2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2019-04-30 US disclosed
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS UNIVERSITY OF UTAH 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134729-A1 METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS CTNNB1, CTNNBL1, WNT3A CDH1 2090/4885CTNNB1 1/4885TCF7L2 31/4885
US-10273246-B2 Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions CTNNB1, CTNNBL1, WNT3A CDH1 2064/4885CTNNB1 1/4885TCF7L2 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.